On June 27, 2018, at Foley Hoag LLC in New York City, the Basser Center for BRCA held a panel discussion on the ins and outs of dating with a BRCA mutation.

The Basser Center's 2018 Breakthroughs and Discoveries Panel brought together some of the world's leading experts in genetic research and hereditary cancer.

The Basser Center's internationally recognized experts in cancer genetics, Susan Domchek, MD, and Katherine Nathanson, MD, are working in collaboration with leading experts in the fields of cancer research and genetics in New York, Los Angeles and Boston to launch the pilot phase of a new, independent research initiative: the BRCA Founder Outreach (BFOR) Study.  Principal Investigators include Dr. Kenneth Offit and Dr. Mark Robson of Memorial Sloan Kettering Cancer Center in New York; Dr. Judy Garber of the Dana Farber Cancer Institute and Dr.

With more than 50 members strong, the Basser Center’s Young Leadership Council (YLC) is an active forum for young adults to become more engaged with the mission of the Basser Center, stay informed about the latest advances in BRCA-related cancer research, and advocate and raise awareness about BRCA mutations and the Center.

On January 25, the Basser Center for BRCA, UJA-Federation of New York, and the 92nd Street Y teamed up in New York City to present a panel on BRCA mutations and the latest lifesaving information surrounding hereditary cancers. Moderated by Joan Lunden, the panel included Basser Center Executive Director Susan Domchek, MD, Memorial Sloan Kettering’s Mark Robson, MD, community educator Nicole Schreiber-Agus, PhD, and author and breast cancer advocate Elizabeth Wurtzel. The discussion primarily focused on the importance of education, awareness, and genetic testing.

A phase II clinical trial that began in August of 2017, “A Phase 2, Open Label Study of Rucaparib in Patients With Advanced Pancreatic Cancer and a Known Deleterious Germline or Somatic BRCA or PALB2 Mutation,” is enrolling patients at the Hospital of the University of Pennsylvania. The trial will determine whether rucaparib, a PARP inhibitor, can be used as a maintenance therapy after at least four months of chemotherapy on pancreatic cancer patients with BRCA1, BRCA2, or PALB2 mutations.

Phil Basser, patriarch of the Basser family, has recently made it into the news for his legendary love of the Philadelphia Eagles. When another 99-year old football fan, Minnesota Vikings fanatic Millie Wall, got some attention for her lifelong fandom, Phil’s grandkids stepped up to the plate. As the PhillyVoice wrote, "To say Basser is a lifelong Birds fan is technically incorrect – not because it's hyperbole but because he is older than the franchise, born 15 years before the Eagles played their inaugural NFL season in 1933."

Watch the full story from Fox News:

Meet the Basser Center’s Young Leadership Council (YLC)! With more than 50 members, the YLC serves as an active forum for young adults to become more engaged with the mission of the Basser Center, stay informed about the latest advances in BRCA-related cancer research, and advocate and raise awareness of BRCA and the Center. Through personal philanthropy and fundraising events, this committed group supports innovative BRCA-related cancer research, patient care, and educational priorities. 

The Basser Center for BRCA is raising awareness about hereditary cancer through our #INVISIBLEGENES social media campaign and we need your help! The traits we inherit from our family define and connect us in countless ways. Sometimes these traits are obvious, like curly hair or dimples. But sometimes what we inherit remains hidden, like BRCA gene mutations which can increase your risk for developing certain type of cancers.

2017 marks an important milestone for the Basser Center for BRCA: it’s our five year anniversary as the first comprehensive center and global hub for the research, treatment, and prevention of BRCA-related cancers. Our unique model includes a devotion to advancing care for people affected by BRCA gene mutations, as well as providing funding for collaborative research, education, and outreach programs around the world. And in the last five years, our mission has come a long way.